PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

PAR. SP, page-361

  1. 7,518 Posts.
    lightbulb Created with Sketch. 6772
    Biotech M&A, the one thing that might offset overwhelming funding fears crippling the share prices of most non-FCF companies on the ASX, has been very quiet of late. Let's hope PR finally fulfills on one of those long hinted at partnerships.....
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.